ライフサイエンスコーパス: nonischemic

1 usted hazard ratio for Chagasic versus other nonischemic: 1.49 (95% confidence interval, 1.15-1.94; P

2 +/- 9 y old) with ischemic (22 patients) and nonischemic (18 patients) heart failure completed the st

3 up for ischemic (19% DZ, 59% TZ, 22% NZ) and nonischemic (6% DZ, 45% TZ, 15% NZ) patients.

4 emic (79% vs. 64% at 2 years; p = 0.004) and nonischemic (88% vs. 71% at 2 years; p = 0.015) subgroup

5 e 50% and 19% of patients, both ischemic and nonischemic, achieved an LV ejection fraction >/= 40%.

6 noninvasive differentiation of ischemic and nonischemic acute heart failure (AHF) in the emergency d

7 troscopy in nondiabetic, lean, predominantly nonischemic, advanced heart failure patients at the time

8 gnificantly higher in ischemic compared with nonischemic AHF (1097 [604-1525] pg/mL versus 800 [427-1

9 gnificantly higher in ischemic compared with nonischemic AHF patients (0.040 [0.010-0.306] mug/L vers

10 and cardiomyocyte damage than patients with nonischemic AHF.

11 s finding is present in 30% of patients with nonischemic and 15% of patients with ischemic cardiomyop

12 clerotic stroke, hypertensive heart disease, nonischemic and Chagas cardiomyopathies, rheumatic heart

13 horylation of RyR2 in patients and mice with nonischemic and ischemic forms of HF.

14 the types of geometric mitral regurgitation (nonischemic and ischemic origins), standardization of ec

15 with symptomatic heart failure (ischemic and nonischemic) and an ejection fraction (EF) of 40% or les

16 elated differences in etiology (ischemic vs. nonischemic) and outcomes (all-cause mortality and death

17 1.4 per 100 person-years for Chagasic, other nonischemic, and ischemic patients, respectively-adjuste

18 effect on CNV formation in a rabbit model of nonischemic angiogenesis.

19 ly inhibited in cardiomyocytes isolated from nonischemic area 7 days after MI.

20 Strain measurements in the nonischemic basal segments also demonstrated a significa

21 S2814 on RyR2 was increased in patients with nonischemic, but not with ischemic, HF.

22 classified ganglia from normal, scarred, and nonischemic cardiomyopathic hearts without scar as NL (n

23 Mean neuronal size in normal, scarred, and nonischemic cardiomyopathic hearts without scar groups w

24 increased in patients with both ischemic and nonischemic cardiomyopathies and also in patients with c

25 The nonischemic cardiomyopathies are a diverse group of card

26 ction of ischemic heart disease, and discuss nonischemic cardiomyopathies unique to or prevalent in w

27 ogeneses, including coronary artery disease, nonischemic cardiomyopathies, and arrhythmias.

28 d the spectrum of imaging appearances of the nonischemic cardiomyopathies.

29 e erratic/patchy scar patterns seen in other nonischemic cardiomyopathies.

30 ardiomyopathy, myocarditis, and ischemic and nonischemic cardiomyopathies.

31 versus 50% in class III and IV, P<0.01), and nonischemic cardiomyopathy (44% versus 27%, P<0.01) and

32 short axis) was applied in 31 patients with nonischemic cardiomyopathy (50+/-18 years).

33 Forty-five patients with nonischemic cardiomyopathy (60+/-16 years; left ventricu

34 Nineteen consecutive patients with nonischemic cardiomyopathy (age 58+/-14 years, 79% men,

35 reparations from human hearts with end-stage nonischemic cardiomyopathy (heart failure, n=10) and non

36 Enrollment criteria were new diagnosis of nonischemic cardiomyopathy (left ventricular ejection fr

37 ysfunction in patients with left ventricular nonischemic cardiomyopathy (LVCM).

38 2000 patients with ischemic (n=805, 40%), or nonischemic cardiomyopathy (n=927, 46%), or congenital/i

39 of ventricular arrhythmias in patients with nonischemic cardiomyopathy (NIC).

40 nce of late potentials (LP) in patients with nonischemic cardiomyopathy (NICM) and ischemic cardiomyo

41 Compared with patients with nonischemic cardiomyopathy (NICM) and ischemic cardiomyo

42 on outcome in patients with left ventricular nonischemic cardiomyopathy (NICM) and suspected epicardi

43 ricular tachyarrhythmias among patients with nonischemic cardiomyopathy (NICM) enrolled in the MADIT-

44 Small-scale studies focused mainly on nonischemic cardiomyopathy (NICM) have shown that a subs

45 of protecting patients with newly diagnosed nonischemic cardiomyopathy (NICM) or ischemic cardiomyop

46 therapy in ischemic cardiomyopathy (ICM) and nonischemic cardiomyopathy (NICM) patients and to evalua

47 resonance (CMR) predict adverse outcomes in nonischemic cardiomyopathy (NICM) patients.

48 rse cardiovascular outcomes in patients with nonischemic cardiomyopathy (NICM).

49 T-D) versus pacing (CRT-P) for patients with nonischemic cardiomyopathy (NICM).

50 ociation [NYHA] functional class I or II) or nonischemic cardiomyopathy (NYHA functional class II onl

51 Unipolar low-voltage distribution in nonischemic cardiomyopathy allows categorization of scar

52 alence of LAVA adjacent to CAs was higher in nonischemic cardiomyopathy and arrhythmogenic right vent

53 elops in tandem with progressive ischemic or nonischemic cardiomyopathy and can improve with antiremo

54 Compared with patients with nonischemic cardiomyopathy and ischemic cardiomyopathy,

55 ival between CCMP patients and patients with nonischemic cardiomyopathy and ischemic cardiomyopathy.

56 Female patients were more likely to have nonischemic cardiomyopathy and left bundle branch block

57 y of the planar QRS-T angle in patients with nonischemic cardiomyopathy and to assess QRS-T angle beh

58 ter ventricular tachycardia (VT) ablation in nonischemic cardiomyopathy are high and the optimal proc

59 of statins in HF patients with ischemic and nonischemic cardiomyopathy as well as potential concerns

60 rsal of end-stage heart failure secondary to nonischemic cardiomyopathy can be achieved in a substant

61 lic heart failure as a result of ischemic or nonischemic cardiomyopathy despite receiving guideline-d

62 res with scar morphology and distribution in nonischemic cardiomyopathy has not been investigated.

63 We randomized 16 patients with nonischemic cardiomyopathy in a double-blind fashion to

64 ong Latin American immigrants diagnosed with nonischemic cardiomyopathy in Los Angeles.

65 Nonischemic cardiomyopathy is a common cause of left ven

66 d, crossover, randomized phase II-a trial of nonischemic cardiomyopathy patients with left ventricula

67 d, crossover, randomized phase II-a trial of nonischemic cardiomyopathy patients with left ventricula

68 ocities, myocardial scar, and wall motion in nonischemic cardiomyopathy patients.

69 Of 435 patients with nonischemic cardiomyopathy referred for VT ablation, 21

70 We studied 28 patients with nonischemic cardiomyopathy requiring VAD support consist

71 alence of LAVAs adjacent to PN was higher in nonischemic cardiomyopathy than in ischemic cardiomyopat

72 s from 455 patients in the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation (DEFINIT

73 n Trial II (MADIT-II), the Defibrillators in Nonischemic Cardiomyopathy Treatment Evaluation Trial (D

74 Fifteen patients with nonischemic cardiomyopathy underwent late gadolinium-enh

75 in endomyocardial biopsies of patients with nonischemic cardiomyopathy was positively correlated wit

76 In 235 patients with chronic ischemic and nonischemic cardiomyopathy with a left ventricular eject

77 mild to moderately symptomatic patients with nonischemic cardiomyopathy with frequent or complex vent

78 relate distinct scar distributions found in nonischemic cardiomyopathy with ventricular tachycardia

79 s involving 8716 4 (1781 patients) addressed nonischemic cardiomyopathy, 6 (4414 patients) ischemic c

80 and followed 1820 patients with ischemic or nonischemic cardiomyopathy, an ejection fraction of 30%

81 h reduced ejection fraction, 1300 with other nonischemic cardiomyopathy, and 1057 with ischemic cardi

82 49 patients (15 ischemic cardiomyopathy, 15 nonischemic cardiomyopathy, and 14 arrhythmogenic right

83 ronic lung disease, cerebrovascular disease, nonischemic cardiomyopathy, and lower ejection fractions

84 pproaches have increased ablation success in nonischemic cardiomyopathy, but the use for postinfarcti

85 In this pilot study of patients with nonischemic cardiomyopathy, itMSC therapy was safe, caus

86 All patients had nonischemic cardiomyopathy, New York Heart Association c

87 In the 6 patients with nonischemic cardiomyopathy, the low-voltage area by far

88 In patients with nonischemic cardiomyopathy, VT and septal scar, delayed

89 ith increased mortality rate in ischemic and nonischemic cardiomyopathy, which may be attributed to e

90 reas of abnormal innervation than those with nonischemic cardiomyopathy.

91 s often close to CAs and PN in patients with nonischemic cardiomyopathy.

92 red ECV and segmental myocardial function in nonischemic cardiomyopathy.

93 Ds with all-cause mortality in patients with nonischemic cardiomyopathy.

94 of adverse clinical outcome in patients with nonischemic cardiomyopathy.

95 creatinine<1.0 mg/dL, QRS 130 to 160 ms, and nonischemic cardiomyopathy.

96 ntricular tachycardias (VT) in patients with nonischemic cardiomyopathy.

97 and reduce infarct size in both ischemic and nonischemic cardiomyopathy.

98 f arrhythmogenic substrates in patients with nonischemic cardiomyopathy.

99 en known for decades as a reversible form of nonischemic cardiomyopathy.

100 morphology and distribution in patients with nonischemic cardiomyopathy.

101 h (primary prevention ICDs) in patients with nonischemic cardiomyopathy.

102 r tachycardia circuit sites in patients with nonischemic cardiomyopathy.

103 tachycardia (VT) substrate is challenging in nonischemic cardiomyopathy.

104 emia-tolerant MSCs (itMSCs) in patients with nonischemic cardiomyopathy.

105 of arrhythmogenic substrate in patients with nonischemic cardiomyopathy.

106 substrate for arrhythmia in human end-stage nonischemic cardiomyopathy.

107 hology and functional characteristics of the nonischemic cardiomyopathy.

108 rapy (control) in at least 100 patients with nonischemic cardiomyopathy.

109 emic cardiomyopathy compared with those with nonischemic cardiomyopathy.

110 cing all-cause mortality among patients with nonischemic cardiomyopathy.

111 ty patients had ischemic and 37 patients had nonischemic cardiomyopathy.

112 or death (HR, 1.99; P<0.001) as left BBB and nonischemic cardiomyopathy.

113 with ischemic cardiomyopathy and those with nonischemic cardiomyopathy.

114 explanted hearts of patients with end-stage nonischemic cardiomyopathy.

115 of various causes in adults with ischemic or nonischemic cardiomyopathy.

116 duce all-cause mortality among patients with nonischemic cardiomyopathy.

117 heart failure (HF) secondary to ischemic and nonischemic cardiomyopathy.

118 myocarditis, neurogenic pulmonary edema, and nonischemic cardiomyopathy.

119 Differentiation of ischemic from nonischemic cardiomyopathy; evaluation of myocardial per

120 reatest changes occurring in patients with a nonischemic cause of heart failure.

121 In the absence of clear demonstration of a nonischemic cause, treatment should include guideline-re

122 sistently demonstrate an ability to identify nonischemic causes (myocarditis, infiltrative disease).

123 ase in LV ejection fraction in patients with nonischemic causes of heart failure.

124 Fifty-five patients with a nonischemic central retinal vein occlusion (CRVO) who we

125 atively homogenous group of 53 patients with nonischemic chronic cardiomyopathy (CCM) was selected fo

126 tes to vessel growth under both ischemic and nonischemic conditions and provide the first evidence th

127 addition to ischemic heart disease, certain nonischemic conditions may also have sex-specific differ

128 Under nonischemic conditions, it is feasible to measure myocar

129 ive capacity of hCPCs in young patients with nonischemic congenital heart defects for potential use i

130 capacity of CSCs in very young patients with nonischemic congenital heart defects has not been explor

131 evaluated Ngb mRNA and protein expression in nonischemic control as well as ischemic mice and its eff

132 te, and it is the first to associate it with nonischemic CRVO.

133 By using two models of infarction, nonischemic cryoinjury and the pathologically relevant c

134 s with ischemic DCM but not in patients with nonischemic DCM.

135 rwent robotic mitral valve repair for severe nonischemic degenerative MR.

136 We profiled the microbiomes of neuropathic nonischemic DFUs without clinical evidence of infection

137 Patients with nonischemic dilated cardiomyopathy (DCM) may be at lower

138 Nonischemic dilated cardiomyopathy (DCM) often has a gen

139 s, both in ischemic cardiomyopathy (ICM) and nonischemic dilated cardiomyopathy (DCM).

140 with left ventricular dysfunction caused by nonischemic dilated cardiomyopathy (mean left ventricula

141 of ventricular tachycardia (VT) ablation in nonischemic dilated cardiomyopathy (NIDCM) are insuffici

142 entricular tachycardia (VT) in patients with nonischemic dilated cardiomyopathy (NIDCM) are insuffici

143 sequences were obtained in 20 patients with nonischemic dilated cardiomyopathy (NIDCM), 20 patients

144 cardiomyopathy, few studies exist in chronic nonischemic dilated cardiomyopathy (NIDCM).

145 and prognostic information in patients with nonischemic dilated cardiomyopathy (NIDCM).

146 tients (18 ischemic cardiomyopathy [ICM], 13 nonischemic dilated cardiomyopathy [NICM], 15 arrhythmog

147 c fibrosis and inflammation in patients with nonischemic dilated cardiomyopathy and inflammatory card

148 In patients with nonischemic dilated cardiomyopathy and VT, endocardial a

149 entricular tachycardia (VT) in patients with nonischemic dilated cardiomyopathy can be challenging be

150 , the most common cause of heart failure was nonischemic dilated cardiomyopathy in 27.5% (whites, 19.

151 Risk stratification of patients with nonischemic dilated cardiomyopathy is primarily based on

152 ography (TTE) in ischemic cardiomyopathy and nonischemic dilated cardiomyopathy patients evaluated fo

153 ive patients with ischemic cardiomyopathy or nonischemic dilated cardiomyopathy undergoing cardiovasc

154 atients (aged 59+/-15 years, 80% males) with nonischemic dilated cardiomyopathy who underwent CA.

155 l patients (164 ischemic cardiomyopathy, 150 nonischemic dilated cardiomyopathy), the mean left ventr

156 ed cardioprotective effect of VEGF-B(167) in nonischemic dilated cardiomyopathy, which limits apoptot

157 chyarrhythmias/sudden death in patients with nonischemic dilated cardiomyopathy.

158 ictors of arrhythmic events in patients with nonischemic dilated cardiomyopathy.

159 on for sudden cardiac death in patients with nonischemic dilated cardiomyopathy.

160 tic information beyond LVEF in patients with nonischemic dilated cardiomyopathy.

161 D34(+) cell transplantation in patients with nonischemic dilated cardiomyopathy.

162 ls of cardiomyopathy, including ischemic and nonischemic dilated cardiomyopathy.

163 of endocardial and adjuvant epicardial CA in nonischemic dilated cardiomyopathy.

164 (HR, 0.39 [CI, 0.23 to 0.68]) and those with nonischemic disease (HR, 0.44 [CI, 0.17 to 1.12]).

165 py was similar in subjects with ischemic and nonischemic disease.

166 d in a subset of patients, both ischemic and nonischemic, early improvement in myocardial structure a

167 the limit of detection in combination with a nonischemic ECG may successfully rule out AMI in patient

168 epartment with normal initial troponin and a nonischemic ECG.

169 e limit of detection (<0.005 microg/L) and a nonischemic electrocardiogram (ECG) to rule out AMI in a

170 Eligible patients had a nonischemic electrocardiogram determined and high-sensit

171 in patients with normal initial troponin and nonischemic electrocardiogram.

172 e gender (HR 0.77 [95% CI 0.69 to 0.85]) and nonischemic etiology (HR 0.80 [95% CI 0.72 to 0.89]) wer

173 ry were age <50 years (odds ratio [OR] 2.5), nonischemic etiology (OR 5.4), time since initial diagno

174 5% primary prevention ICD) with ischemic and nonischemic etiology undergoing first ICD implant at 1 o

175 Predictors of reverse remodeling were nonischemic etiology, female sex, and a wider QRS durati

176 e older, female, and Caucasian and to have a nonischemic etiology.

177 mic attack 114.5 pmol/l (85.3 to 138.8); and nonischemic event 102.8 pmol/l (76.4 to 137.6; both grou

178 c attack (n = 16; 8.5%) and to patients with nonischemic events (n = 49; 25.9%): median (interquartil

179 scularization was deferred on the basis of a nonischemic FFR (>0.75).

180 aneous coronary intervention on the basis of nonischemic FFR in patients with an initial presentation

181 ronary intervention deferred on the basis of nonischemic FFR.

182 A nonischemic forearm test demonstrated a lack of increase

183 reticulum Ca(2+) leak and HF development in nonischemic forms of HF such as transverse aortic constr

184 y differentiate between ischemic and various nonischemic forms of myocardial injury, it may be helpfu

185 Mechanisms and treatments of nonischemic functional mitral regurgitation (NIMR) are n

186 Aging impairs function in the nonischemic heart and is associated with mechanical remo

187 ator implantation is recommended in dilated, nonischemic heart disease and left ventricular ejection

188 nhibition exerts an antiremodeling effect in nonischemic heart disease in humans.

189 14 years; 79% men) with sustained VT due to nonischemic heart disease were included.

190 In patients with recurrent VT due to nonischemic heart disease, catheter ablation is often us

191 arkers may improve identification of SBHF in nonischemic heart disease.

192 HF is present among adults with HF caused by nonischemic heart disease.

193 ablation of ventricular tachycardia (VT) in nonischemic heart diseases can be challenging, and outco

194 s (CFBs) to promote cardiac fibrosis (CF) in nonischemic heart failure (HF).

195 imary etiologic factor in the development of nonischemic heart failure (HF).

196 vious history of MI compared with those with nonischemic heart failure and correlated with survival,

197 The majority (71%) of patients with nonischemic heart failure etiology or functional block r

198 Whether the myocardium in nonischemic heart failure experiences oxygen limitation

199 Our study suggests that novel treatments for nonischemic heart failure should focus on efforts to dir

200 an affordable and effective new therapy for nonischemic heart failure.

201 ife for patients afflicted with ischemic and nonischemic heart muscle disorders.

202 ease in Cripto-1 expression as compared with nonischemic heart tissue samples, suggesting that hypoxi

203 of 10 microM BH(4) enhanced eNOS activity in nonischemic hearts and partially restored activity after

204 tratified by diabetes status and ischemic or nonischemic HF and history of revascularization in the S

205 study examined the impact of ischemic versus nonischemic HF and previous revascularization on long-te

206 r HF diagnosis (classified as ischemic HF or nonischemic HF based on the presence of IHD) was assesse

207 d patients were more likely to be women with nonischemic HF etiology, higher baseline blood pressure,

208 also related biomarkers to the incidence of nonischemic HF in participants without prevalent coronar

209 The risk of nonischemic HF increased rapidly after RA onset, in cont

210 The increased risk of nonischemic HF occurred early and was associated with RA

211 Real-time videomicroscopy of T cells from nonischemic HF patients or from mice with HF induced by

212 l infiltration in the fibrotic myocardium of nonischemic HF patients, as well as the protection from

213 nsulin resistance is highly prevalent in the nonischemic HF population, predates the development of H

214 002), and were independently associated with nonischemic HF risk.

215 r subsequent HF (any type), ischemic HF, and nonischemic HF were between 1.22 and 1.27.

216 k of HF overall and by subtype (ischemic and nonischemic HF) in patients with RA and to assess the im

217 I-1c (BNP116.I-1c) in a preclinical model of nonischemic HF, and to assess thoroughly the safety of B

218 f perivascular CF and cardiac dysfunction in nonischemic HF.

219 T cells are major contributors to nonischemic HF.

220 port the link between insulin resistance and nonischemic HF.

221 tricle and atrium in a large animal model of nonischemic HF.

222 ith all HF types but was most pronounced for nonischemic HF.

223 A total of 1121 patients with nonischemic HFREF from the beta-blocker Evaluation of Su

224 Using various in vivo, nonischemic, hindlimb xenotransplant models (immunocompe

225 scle regions of interest in the ischemic and nonischemic hindlimbs for quantification of regional cha

226 eased Galphaq palmitoylation in ischemic and nonischemic hindlimbs in vivo In summary, we demonstrate

227 of reduction was similar in the cohorts with nonischemic (HR, 0.81 [CI, 0.72 to 0.91]) and ischemic (

228 to death or hospitalization was longer among nonischemics (HR 0.83 [95% CI 0.78 to 0.89], p < 0.0001)

229 chemics, HR 0.83 [95% CI 0.81 to 0.85]; male nonischemics, HR 0.84 [95% CI 0.83 to 0.85]; male ischem

230 imates varied by gender and etiology (female nonischemics, HR 0.88 [95% CI 0.85 to 0.89]; female isch

231 ped in a clinically relevant murine model of nonischemic hypertrophic CHF, transverse aortic constric

232 ive acting adenosine, we reasoned that short nonischemic hypoxia also protects against hepatic IRI.

233 WC) of radiotracer activity, and ischemic-to-nonischemic (I/NI) ratio was calculated.

234 myopathy pathogenesis was ischemic in 21 and nonischemic in 13 patients with a mean left ventricular

235 ects; p < 0.05), and focal fibrosis (59% had nonischemic late gadolinium enhancement, as compared wit

236 hanges; the roles of sensitive indicators of nonischemic left ventricular (LV) dysfunction, such as L

237 utcome of competitive athletes with isolated nonischemic left ventricular (LV) scar as evidenced by c

238 erring percutaneous coronary intervention in nonischemic lesions by fractional flow reserve (FFR) is

239 Compared with nonischemic lesions, ischemic lesions had smaller MLD (1

240 Nonischemic LGE patterns (midmyocardial/subepicardial) w

241 Injection of AdCA5 into nonischemic limb was sufficient to increase the number o

242 o a degree that was greater than the control nonischemic limb.

243 s was evaluated visually in the ischemic and nonischemic limbs, and the presence of small collateral

244 issue nitrite and NO metabolites compared to nonischemic limbs.

245 In additional groups of animals, the nonischemic liver lobes were resected at the end of 90-m

246 Isolated nonischemic LV LGE with a stria pattern may be associate

247 rtery diameter measurement were performed in nonischemic mice after unilateral 10-minute exposure to

248 greater opacification in postischemic versus nonischemic myocardium at both time points (P < or = 0.0

249 f remote cardiac macrophages residing in the nonischemic myocardium in mice with chronic heart failur

250 Following myocardial infarction, nonischemic myocyte death results in infarct expansion,

251 ction (n=126) and CHF of ischemic (n=562) or nonischemic (n=87) etiology.

252 Deep sequencing of RNA isolated from paired nonischemic (NICM; n=8) and ischemic (ICM; n=8) human fa

253 e myocardial blood flow in ischemic (IS) and nonischemic (NIS) beds of the left ventricle was determi

254 c magnetic resonance imaging consistent with nonischemic, nonfailing diabetic cardiomyopathy (reduced

255 eft ventricular systolic dysfunction, either nonischemic or ischemic.

256 etiology was categorized as Chagasic, other nonischemic, or ischemic cardiomyopathy.

257 and made up the response score (female sex, nonischemic origin, left bundle-branch block, QRS >/=150

258 rt failure of any cause and heart failure of nonischemic origin.

259 ces of chronic heart failure of ischemic and nonischemic origin.

260 ts affected by heart failure of ischemic and nonischemic origin.

261 In contrast, LBBB is most commonly caused by nonischemic pathologies.

262 enital/inherited heart disease, and 1% among nonischemic patients (P=0.02).

263 ilure results in similar midterm survival to nonischemic patients in hospital survivors.

264 s controls, calf biopsies of nondiabetic and nonischemic patients undergoing saphenous vein stripping

265 A total of 18% of ischemic and 31% of nonischemic patients were women.

266 ischemic patients with CAC scores >1,000 and nonischemic patients with Bayesian coronary artery disea

267 aled similarly low cardiac event rates among nonischemic patients with CAC scores >1,000 and nonische

268 Among the 1,089 nonischemic patients, of which only 3 (0.3%) underwent e

269 cted only 10% of inferior segments in 75% of nonischemic patients.

270 A similar benefit was not seen in the nonischemic patients.

271 low-up (56.7% vs. 27.5%, P = 0.011) than the nonischemic patients.

272 /C-type pattern of fatty infiltration and/or nonischemic pattern LGE).

273 rol; a similar trend was not observed in the nonischemic population.

274 hat is frequently the result of a variety of nonischemic processes.

275 ir origin and roles in post-MI remodeling of nonischemic remote myocardium, however, remain unclear.

276 urthermore, it is currently not known if the nonischemic remote zone recruits monocytes.

277 y higher in victims of ischemic (34.2%) than nonischemic SCD (13.4%; P<0.001) or controls (17.6%; P<0

278 ol study included (1) consecutive victims of nonischemic SCD (n=223), (2) consecutive victims of isch

279 rpose of this study was to determine whether nonischemic SCD has a similar familial background, which

280 ee relatives did not differ from controls in nonischemic SCD victims (P=0.155).

281 is not significantly increased in victims of nonischemic SCD, suggesting a larger role of sporadic oc

282 rrence than inherited traits as the cause of nonischemic SCD.

283 atrial tissue was harvested before CP from a nonischemic segment and after CP from an atrial segment

284 -1); P=0.001), whereas no effect was seen in nonischemic segments (-2.19+/-0.48 versus -2.18+/-0.54 s

285 ifferent concentrations between ischemic and nonischemic segments.

286 , there is little known about the effects of nonischemic stimuli.

287 e for Patients with Mitral Regurgitation and Nonischemic study.

288 sic cardiomyopathy (CC) is the most frequent nonischemic substrate causing left ventricular (LV) tach

289 escribed a remote cardioprotective effect of nonischemic surgical trauma (abdominal incision) called

290 of a primary prevention ICD in patients with nonischemic systolic heart failure warrants further inve

291 was observed in 236 eyes (121 ischemic, 115 nonischemic) that were compared with a control group (10

292 include differentiation between ischemic and nonischemic types, identification of any complications,

293 that shock in a swine model of ischemic and nonischemic ventricular fibrillation arrest.

294 nt of normal versus abnormal (SSS >/= 4) and nonischemic versus ischemic (SDS >/= 2) studies was exce

295 lower radiation exposure than patients with nonischemic VT (total fluoroscopy time, 2.53 [1.22-11.22

296 VT substrate: (1) ischemic VT (IVT) and (2) nonischemic VT and depending on the presence of an epica

297 ibe the outcomes after catheter ablation for nonischemic VT in a large cohort and to compare the elec

298 were performed in 41 patients (22 IVT and 19 nonischemic VT).

299 Relative 201Tl retention (ischemic/nonischemic) was reduced immediately postocclusion in di

300 s with cardiomyopathy (n = 9 ischemic, n = 4 nonischemic) who were scheduled to undergo ablation of d